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Background : Intra-operative analysis of sentinel lymph nodes would enhance the care of 
early stage oral squamous cell carcinoma (OSCC). We aim to determine the frequency and 
extent of cytokeratin 19 (CK19) expression in OSCC primary tumours and surrounding 
tissues to explore the feasibility of a 'clinic-ready' intra-operative diagnostic test (One Step 
Nucleic Acid Amplification - OSNA, Sysmex). 
 
Methods: Two cohorts were assembled: cohort 1, OSCC with stage and site that closely 
match cases suitable for sentinel lymph node biopsy (SLNB): cohort 2, HNSCC with 
sufficient fresh tumour tissue available for the OSNA assay (>50mg). CK19 assays included 
qRT-PCR, RNA in-situ hybridisation (ISH) and immunohistochemistry (IHC), as well as 
OSNA. 
 
Results: CK19 mRNA expression was detected with variable sensitivity, depending on 
method, in 60-80% of primary OSCC tumours, while protein expression was observed in 
only 50% of tumours. Discordance between different techniques indicated that OSNA was 
more sensitive than qRT-PCR or RNA-ISH, which in turn were more sensitive than IHC. 
OSNA results showed CK19 expression in 80% of primary cases, so if used for diagnosis of 
lymph node metastasis would lead to a false negative result in 20% of patients with cervical 
lymph node metastases. 
 
Conclusions: OSNA in is current form is not suitable for use in OSCC SLNB owing to 
inadequate expression of the CK19 target in all case. However, the same assay technology 
would likely be very promising if applied using a more ubiquitous squamous epithelial target. 
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Synopsis:  The expression of cytokeratin 19 (CK19) expression in oral cancer (OSCC) was 
60-80%. OSNA (One Step Nucleic Acid Amplification) was more sensitive than other RNA 
assays or immunohistochemistry. CK19 OSNA would lead to unacceptable (20%) false 
negative results for sentinel lymph node biopsy. 
Introduction  
 
Renewed interest in sentinel lymph node biopsy (SLNB) for early stage oral squamous cell 
carcinoma (OSCC) has resulted from reassuring data with 95% negative predictive value 
(NPV)
1,2
, and also recent trials reinforcing the survival benefit of surgical neck staging
3
.  A 
significant drawback of SLNB is that, in the event of a positive lymph node, a costly (and 
more morbid) second surgical episode is necessitated. This delay mandated by serial 
examination of SLN, delays the commencement of adjuvant therapy and creates additional 
patient distress. SLNB in OSCC would be facilitated by intra-operative staging however 
frozen section analysis has been found to be somewhat insensitive
4,5
, certainly highly 
operator dependent, and has not found general acceptance
6
. PCR-based techniques have been 
reported for head and neck squamous cell carcinoma (HNSCC) 
7,8
 but lack a ‘clinic-ready’ 
platform.  
One-step nucleic acid amplification (OSNA) uses loop-mediated isothermal amplification 
(LAMP)
9
, amplifying RNA with high sensitivity, specificity, efficiency and rapidity under 
isothermal conditions. OSNA employs six specially designed primers at eight sequences 
within CK19 mRNA subtending high sensitivity and specificity.  In breast cancer, OSNA has 
been validated to at least 96%
10
 concordance with histopathology, has been widely adopted 
and approved in UK NICE guidelines
11
. OSNA necessitates an additional 30-40 minutes 
operative time, but avoids second surgeries and accelerates commencement of adjuvant 
therapies from 8.4 to 6.2 weeks 
12
. 
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In HNSCC the clinical potential of OSNA is unproven, and careful validation is required. 
Although gene signatures for OSCC or epithelial tissue have been developed with sensitive 
RT-PCR using other target cytokeratins
8
, or PVA/EPCAM
7
, the opportunity around CK19 is 
the availability of a ‘clinic-ready’ diagnostic test with stringent quality assurance. Several 
reports have shown that CK19 is a component of the cytoskeleton of HNSCC
13,14
 and qRT-
PCR for cytokeratins appear sensitive and specific in detecting cervical lymph node 
metastasis in HNSCC
8,15
. CK19 OSNA has recently been validated for lymph node staging in 
colorectal
16,17
 and stomach
18,19
 adenocarcinoma. The extent of CK19 expression in HNSCC, 
and therefore whether OSNA could have clinical utility, remains unproven.  
Goda et al
20
 analysed 213 HNSCC lymph nodes with CK19 OSNA, suggested an overall 
accuracy of 94% per node and 94% per patient. Matsuzuka et al
21
 found a NPV of 95.9% in 
HNSCC. Suzuki examined CK19 expression in HSNCC, finding a lower rate of expression 
and suggesting that clinical use of OSNA only in a selected subset of HNSCC known to be 
CK19 positive
22
. All three studies were undertaken in a Japanese population with a variety of 
stages and sites of HNSCC, for example Goda et al
20
 report on cT1-4 and N0-3 OSCC and 
Matsuaka et al.
21
 report on a combination of HNSCC sites and also include advanced stages.  
As SLNB is routinely offered only to cT1-2N0 OSCC, these reports do not ideally reflect the 
target clinical population in question. It remains uncertain if the expression of CK19 is 
sufficiently high and uniform to make the CK19 OSNA suitable for use in OSCC SLNB. 
The aim of this study is to establish the frequency and extent of CK19 expression in primary 
OSCC and surrounding, potentially contaminating, tissues. We aim to establish expression of 
CK19 mRNA using both OSNA and other techniques, as well as protein expression.  In the 
event that CK19 expression is <95% we will pilot assays to be used on diagnostic biopsies of 
primary tumours in order to stratify them as suitable, or not, for OSNA analysis of SLNB. 
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Lastly we aim to test the concordance between matched primary tumour and metastatic 
lymph node in CK19 expression. 
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Methods  
Tissue  
A clinical cohort was assembled from the tissue banks of the Universities of Liverpool and 
Copenhagen with appropriate ethical approvals and consent. Clinicopathological 
characteristics and results are summarised in Supplemental table S1. 
Cohort 1 (43 cases from Liverpool) met the criteria:  OSCC, clinical stage cT1N0 and 
cT2N0, formalin-fixed paraffin-embedded (FFPE) and fresh frozen tumour tissue available.  
The OSNA assay interrogates fresh (or frozen) sentinel lymph nodes >50mg, preferably in 
their entirety. This presented an ethical and logistic barrier as the lymph nodes are required 
for histopathological staging, and banked primary tumour samples were exclusively <50mg 
in T1/T2 OSCC. We therefore elected to analyse primary tumour in order to establish CK19 
expression using a number of assays, excluding OSNA. 34/43 had available matched FFPE 
lymph nodes. 
Cohort 2 (87 cases, 44 Liverpool and 43 Copenhagen) met the criteria: OSCC, >50mg snap 
frozen primary tumour tissue, most of these were cT3/4 cases.  
Tissue preparation & handling: 
Cohort 1: Immunohistochemistry (IHC): 4µm sections were stained for CK19 protein by two 
methods: a mouse monoclonal antibody (clone b170, Leica Biosystems) on a Ventana 
Benchmark Ultra Autostainer (Ventana Medical Systems Inc.) at a dilution of 1:100 using 
standard retrieval conditions (MMC1) and the detection polymer Ultraview (Ventana Medical 
Systems Inc): a mouse monoclonal antibody (clone RCK 108, Dako) diluted 1:100 and the 
EnVision FLEX  system on an Autostainer Link 48 instrument (Dako) using high pH antigen 
retrieval. Negative controls omitted addition of the primary antibody.   
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in situ hybridization (ISH): CK19 RNA ISH was carried out on 4µm  FFPE sections using 
proprietary reagents (RNAscope, Advanced Cell Diagnostics Inc.).  Sections were 
deparaffinised and pre-treated with heat and protease before hybridisation with target-specific 
probes: CK19, PPIB (constitutively expressed endogenous gene; positive control) and dapB 
(bacterial mRNA; negative control) in a dedicated hybridization oven (HybEZ oven, 
Advanced Cell Diagnostics Inc.).  Probe hybridization was detected using the chromogen 
3,3’-diaminobenzidine (DAB).   
Both IHC and ISH techniques were optimized using known positive (breast ductal 
carcinoma) and negative tissue (lymph node).  Tissue cores from controls constituted a 
‘control block’, sections of which were mounted on each test slide to quality assure the 
staining methods.  The tests were scored by two pathologists (MR & AT). Staining was 
assessed by assigning an intensity score (0, no staining; 1, weak; 2, moderate; 3, strong) and 
percentage of malignant cells stained.  These were used to calculate an H score (product of 
intensity and percentage), but also classified in a binary fashion (positive vs. negative). 
RNA was prepared from fresh frozen tissue of primary tumours using an miRNeasy kit 
(Qiagen), and following reverse transcription (cDNA kit, Applied Biosystems), a CK19 qRT-
PCR assay was prerformed with the following primers/probe; Fwd: 
5’CACTACTACACGACCATCCAGGAC 3’, Rev: 5’ CGGAAGTCATCTGCAGCCA 3’, 
Probe: 5’ TAMRA-ACGGGCATTGTCGATCTGCAGGAC-BHQ2. The qPCR reaction 
utilised the Universal Master Mix II (Applied Biosystems) , the thermal profile: 50
o
C for 2 
min, 95 
o
C for 10 min, 45 cycles of 95 
o
C for 15sec and 60 
o
C for 1 min, using a 7500 FAST 
instrument (Applied Biosystems). The relative quantification (RQ) value was calculated as: 
RQ = 2
–Ct , where Ct is the cycle threshold for each target. 
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Cohort 2: OSNA: OSCC biopsies from cohort 2 with mass between 50 and 600 mg were 
snap frozen and stored at -80°C until shipment to Sysmex on dry ice. Samples were 
processed according to manufacturer’s instructions (Sysmex, Kobe, Japan) using a designated 
instrument (RD-100i) and reagent system (LYNOAMP & LYNORHAG). Individual tumour 
samples were placed in 4 ml of homogenizing buffer LYNORHAG (0.2 M glycine-HCl pH 
3.5, 5% Brij35 and 20% DMSO), and homogenised for 60 s at 10 000 rpm with a Polytron 
System PT1300D (Kinematica AG, Switzerland) and LYNOPREP blades to prepare a 
homogeneous lysate. 1 ml of lysate was centrifuged to remove cell debris and then further 
diluted 1:10 and 1:100 with LYNORHAG. The diluted lysates were used directly for 
amplification without RNA extraction or purification. Isothermal amplification reactions 
were performed at 65°C. The rise time required for precipitation of magnesium 
pyrophosphate to reach a turbidity of 0.1 OD at 465 nm was obtained for each sample and the 
number of CK19 mRNA copies determined using a calibration curve. OSNA was classified 
as following: (-) = < 250 copies; (-L)  = < 250 copies; (+) = > 250 & < 5000 copies, (++) = > 
5000 copies; (++) or (+) were positive results, while (-) or (-L) were negative 
RNA quality was analysed for negative (- or –L) samples in order to exclude false negatives. 
OSNA lysates were processed with the Qiagen RNeasy kit (Qiagen, Venlo, Netherlands). 
Total RNA was quantified spectrophotometrically (260/280 nm ratio). RNA integrity was 
assessed using RNA Integrity Number (RIN) with a Bioanalyser (Agilent, Santa Clara, CA, 
USA).  
RNA was prepared from unused OSNA lysates and from a separate aliquot of fresh frozen 
tissue from the same tumours, reverse transcribed and subject to CK19 qRT-PCR assay as 
described above.  
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Inter-plate qRT-PCR variation was reduced by using the ∆∆Ct method to normalise 
expression with respect to two tumours that had previously been shown to highly express 
CK19. A technical threshold of 0.005 x the mean ∆Ct of the reference tumours was observed 
in two experiments and was adopted to distinguish positive from negative CK19 expression 
in all qRT-PCR experiments.  
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Results 
Cohort 1. Of 43 primary cT1/T2N0 tumours tested with CK19 IHC, 21 (48.8%) were 
positive. 29 of 39 primary tumours evaluable in CK19 RNA ISH tests were CK19 positive 
(74.4%), 4 failed quality assurance checks.  CK19 IHC was concordant with the CK19 RNA 
ISH in 26 of 39 cases (66.7%).  For both tests, the staining was generally weak and 
heterogeneous (Figures 1 & 2) with positive cases having H scores between 5 to 200.  
Discordant cases (n=13) had lower H scores (Mean 42.7, Range 5-160).  Of the 13 discordant 
results, 9 were positive in RNA ISH and negative in IHC, reflecting higher sensitivity of 
RNA ISH. Stage I/II OSCC was less likely to be positive by IHC than stage III/IV (P<0.01). 
No such discrepancy was observed for RNA ISH. 
CK19 IHC and CK19 RNA ISH were concordant in 6 of 8 cases with corresponding lymph 
node metastases, omitting two failed tests (Table 1).  In one case, the primary tumour was 
positive for both tests, but the corresponding lymph node metastasis was negative (patient 
3392: Figure 2, Table 1).  Lymph nodes with no evidence of metastatic carcinoma (n=26) did 
not contain any CK19 positive cells.  There were no epithelial lymph node inclusions 
(salivary or thyroid), however, in one case CK19 positive perinodal salivary gland tissue was 
included in the section, but this might have been dissected free prior to analysis in an SLNB 
protocol.  
18 of 26 (69%) primary cT1/T2N0 tumour tissues were positive for CK19 mRNA by qRT-
PCR. CK19 qRT-PCR was concordant with IHC in 16 of 26 cases (62%) and with CK19 
RNA ISH in 13 of 22 cases (59%)(Table 2).  Discordant IHC cases tended to be positive by 
qRT-PCR (7/10). By contrast, discordant ISH cases were equally likely to be positive or 
negative (4/9 positive by qRT-PCR), however, the ISH positives had lower H scores (mean 
33.0, range 5-160).  
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Cohort 2. Of 87 primary tumour samples analysed by OSNA, 7 were excluded owing to 
compromised RNA integrity (low RIN). Examination of representative, H&E stained sections 
from the 43 Danish samples identified 5 that did not contain tumour tissue by pathological 
examination, one with compromised RNA integrity. The remaining 4 were OSNA positive: 2 
contained oral epithelium and 2 contained salivary tissue. Of 76 tumour samples, 61 (80%) 
were CK19 mRNA positive by OSNA, with no correlation for either tumour stage or site 
(Supplementary table S2).  
39 of the tumours from Liverpool had sufficient tissue to allow extraction of mRNA from a 
separate portion of the tumour. Of these, 23 (59%) were CK19 positive. qRT-PCR data was 
concordant with OSNA data in 29/37 (78%) of cases, with OSNA proving the most sensitive 
test in all 8 discordant cases. In order to investigate this more fully, RNA from the OSNA 
tissue lysates from all 87 samples was subject to qRT-PCR. 4 samples were excluded based 
on the low RNA levels (GAPDH amplification). 56/83 (67%) of these samples were positive 
for CK19 expression, showing concordance with OSNA data in 70/81 (85%) of cases. All 
discordant cases demonstrated positivity by OSNA but were negative by qRT-PCR. 
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Conclusions  
CK19 expression is detectable in between 50 and 80% of OSCC, depending upon the assay 
used.  RNA-ISH and qRT-PCR are more sensitive than IHC, while OSNA appears to be the 
most sensitive method. The prevalence of CK19 expression by OSNA is still, at 80%, 
insufficient to suggest that OSNA could be used without prior screening of biopsy tissue for 
CK19, as it could result in 20% of positive lymph nodes being called as false negative. CK19 
expression in OSCC has been previously reported to range between 53% and 91%
13,14
 and 
our results confirm that CK19 can be detected only in a subset of primary tumours. In this 
regard, OSCC differs from breast, colorectal & stomach sites, all adenocarcinomas, where 
CK19 OSNA has been clinically validated.  Although the chemistry and platform available 
through OSNA appear to be well suited to clinical use in being highly reliable, sensitive and 
specific, the gene target CK19 appears to offer insufficient expression in OSCC for clinical 
application.  Should a more appropriate gene target (perhaps CK5 or 14) be available, it may 
be that this would be suitable, subject to the appropriate and necessary clinical validations. 
Although, theoretically, OSNA might be used on a fresh biopsy sample to select CK19 
positive tumours suitable for OSNA assay in SLNB, concern remains that surrounding oral 
mucosa or salivary gland could be included leading to a false positive. CK19 mRNA ISH 
carried out on an existing FFPE diagnostic biopsy, might be more convenient and provide 
histological context, avoiding false positives. However, our results show that CK19 mRNA 
ISH expression was usually low and heterogeneous, limiting diagnostic confidence and 
making the assay vulnerable to inter-observer variability. Consequently, we could not suggest 
a reliable assay to stratify which tumours are suitable for OSNA assay in SLNB. 
In one case, the primary tumour was positive and the matched lymph node metastasis was 
negative by both CK19 ISH and IHC. Contamination in the neck structures with ectopic 
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salivary (0.9%)
23
 or thyroid tissue (1.5%)
24
 have been reported either within or immediately 
surrounding lymph nodes and could produce false positives in any methodology that uses 
solid specimens. It may be that careful dissection of single SLNB would eliminate this, but 
again a validation study would be helpful. 
Our data successfully incorporated a new assay (CK19 mRNA ISH) and shows potential 
clinical avenues in OSCC for molecular diagnostics. We have CK19 data on 123 OSCC 
which effectively rules out the need for potentially burdensome, and clinically risky, 
validation studies. The international collaboration between two academic head and neck 
cancer centres and industry augers well should a more suitable assay become available.  Such 
an assay might  additionally be applicable to cutaneous SCC and anogenital SCC which 
would increase the test’s commercial viability. It is encouraging that OSNA assays with 
differing gene targets, most recently with MMP7
25
 (matrix-metalloproteinase 7) are available. 
 
The concept of intra-operative diagnostics in OSCC remains attractive, but awaits a suitable 
assay. At present SLNB analysis is based on evaluation of stepped serial sections from only a 
proportion of the sentinel node, thus a rapid technique examining the entire sentinel node for 
tumour deposits may provide more accurate staging.  An automated intra-operative method 
would also avoid the substantial additional workload for the pathology team performing serial 
SLNB examination. In head & neck oncology, intra-operative diagnostics appear even more 
attractive than in melanoma and breast, as OSCC remains largely a surgically treated disease 
and completing all surgery in one operation would facilitate the wider acceptance of SLNB.  
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Supplemental Table S1 Summary of characteristics of tumours and tabulated results for 
cohort 1 and 2 
Supplemental Table S2. Distribution of CK19 expression by OSNA and stage 
 
Table 1 Test results for primary tumours with corresponding lymph node metastases. 
Table 2 qRT-PCR concordance with IHC and ISH staining 
Table 3  Distribution of CK19 mRNA expression by OSNA 
 
Figure 1  A primary tumour that shows weak, heterogeneous CK19 positivity and a 
corresponding sub-capsular lymph node metastasis with stronger CK19 staining. This case 
illustrates the difficulty, with either IHC or ISH, to offer a confident diagnostic test to 
identify cases from diagnostic biopsy suitable for CK19 OSNA. 
Figure 2  A primary tumour that shows weak, heterogeneous CK19 positivity and a 
corresponding lymph node metastasis with no CK19 staining.  If this case had undergone 
SLNB analysis using CK19 OSNA, even with the apparent security of a ‘positive’ primary 
tumour, it is likely that a false negative result would be returned with consequent under-
treatment and neck recurrence.  
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CK19 IHC CK19 ISH 
3567 Primary 
3567 Metastasis 
Figure 1.  A primary tumour that shows weak, heterogeneous 
CK19 positivity and a corresponding sub-capsular lymph 
node metastasis with stronger CK19 staining. 
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CK19 IHC CK19 ISH 
3392 Primary 
3392 Metastasis 
Figure 2.  A primary tumour that shows weak, 
heterogeneous CK19 positivity and a corresponding 
lymph node metastasis with no CK19 staining  
Page 20 of 29
To contact the Journal office: info@asoeditorial.org
Annals of Surgical Oncology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Table 1. Test results for primary tumours with corresponding lymph node metastases. 
 
CK19 IHC CK19 ISH 
Primary Metastasis Primary Metastasis 
3123 
3211 
3352 
3567 
3392 
3549 
3464 
3289 
 
Red = positive 
Blue = negative 
Yellow = not available, test failed quality assurance checks. 
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Table 2 qRT-PCR concordance with IHC and ISH staining 
 
 IHC ISH 
+ - + - 
qRT-PCR + 11 7 11 4 
qRT-PCR - 3 5 5 2 
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Table 3  Distribution of CK19 mRNA expression by OSNA 
 
OSNA Number of samples (%)   
(++) 45 (56%) 
65 
(81%) 
(+) 20 (25%) 
(-) 12 (15%) 
15 
(19%) 
(-L) 3 (4%) 
Total 80 (100%)   
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CK19 
qRT-PCR
pt no Primary vs Met
Tumour 
presence
tumour 
score
node 
score Intensity % H score
tumour 
score.
node 
score. Intensity. %. H score. Comments pos/neg site stage pathology
3123 Primary SCC 1 1 10 10 1 1 10 10 tongue (ventral) 4 pT2N2c
3123 LN SCC 1 1 10 10 1 1 50 50
3149 Primary SCC 0 0 0 0 0 0 0 0 tongue (lateral) 1 pT1N1
3153 Primary SCC 0 0 0 0 1 2 70 140 FOM 2 pT2N0
3165 Primary SCC 1 1 50 50 1 1 20 20 1 tongue (lateral) 2 pT2N0
3165 LN No tumour
3172 Primary SCC 0 0 0 0 0 0 0 0 1 FOM 2 pT2N0
3172 LN No tumour
3188 Primary SCC 0 0 0 0 0 0 0 0 0 FOM 2 pT2N0
3188 LN No tumour  
3211 Primary SCC 1 1 50 50 1 1 20 20 1 buccal 4 pT2N2b
3211 LN SCC 1 1 70 70 1 2 25 50
3212 Primary SCC 0 0 0 0 1 1 20 20 FOM 1 pT1N0
3212 LN No tumour
3229 Primary SCC 0 0 0 0 1 1 50 50 1 tongue (anterior) 2 pT2N0
3232 Primary SCC 1 2 20 40 1 1 10 10 1 FOM 1 pT1N0
3232 LN No tumour CK19 ISH background
3258 Primary SCC 1 1 70 70 1 1 50 50 1 FOM 2 pT2N0
3258 LN No tumour
3274 LN No tumour
3274 Primary SCC 1 1 90 90 1 1 20 20 0 tongue (ventral) 3 pT2N1
3288 LN No tumour
3288 Primary SCC 1 1 20 20 1 2 50 100 1 tongue (ventral) 1 pT1N0
3289 Primary SCC 0 0 0 0 CK19 ISH internal control negative 1 FOM 3 pT2N1
3289 LN SCC 0 0 0 0 0 0 0 0
3333 Primary SCC 0 0 0 0 0 0 0 0 CK19 ISH internal control weak tongue (ventral) 2 pT2N0
3333 LN No tumour 0 0 0 0 CK19 ISH internal control weak
3340 Primary SCC 1 1 100 100 1 1 5 5 tongue (ventral) 2 pT2N0
3340 LN No tumour
3341 Primary SCC 0 0 0 0 1 2 10 20 tongue (ventral) 2 pT2N0
3352 LN SCC 1 2 100 200 1 2 70 140
3352 Primary Adenosq. ca. 1 2 100 200 1 2 100 200 FOM 4 pT2N2b
3355 Primary SCC 0 0 0 0 1 1 50 50 tongue 1 pT1N0
3355 LN No tumour
3364 Primary SCC 0 0 0 0 1 2 50 100 tongue 2 pT2N0
3361 Primary SCC 1 1 20 20 0 0 0 0 tongue 2 pT2N0
3361 LN No tumour
3379 Primary SCC 1 1 5 5 1 1 60 60 buccal 2 pT2N0
3379 LN No tumour
3392 Primary SCC 1 2 70 140 1 2 80 160 0 FOM 3 pT2N1
3392 LN SCC 0 0 0 0 0 0 0 0
3395 Primary SCC 1 1 80 160 0 0 0 0 FOM 2 pT2N0
3395 LN No tumour
3394 Primary SCC 0 0 0 0 0 0 0 0 CK19 ISH internal control weak 1 tongue 1 pT1N0
Clinicopathological dataCK19 IHC CK19 mRNA ISH
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3394 LN No tumour
3399 Primary SCC 0 0 0 0 1 1 50 50 tongue 2 pT2N0
3399 LN No tumour
3401 Primary SCC 1 1 20 20 1 2 70 140 1 tongue (ventral) 1 pT1N0
3401 LN No tumour
3408 Primary SCC 0 0 0 0 0 0 0 0 0 tongue (ventral) 2 pT2N0
3423 Primary SCC 1 2 80 160 1 2 60 120 1 FOM 2 pT2N0
3423 LN No tumour
3441 Primary SCC 1 1 10 10 1 2 60 120 1 tongue (lateral) 2 pT2N0
3441 LN No tumour
3458 Primary SCC 1 2 80 160 1 2 90 180 1 FOM 2 pT2N0
3460 Primary SCC 1 1 10 10 1 1 10 10 0 tongue 1 pT1N0
3460 LN No tumour
3462 Primary SCC 0 0 0 0 CK19 ISH tumour cut out 1 FOM 2 pT2N0
3464 Primary SCC 1 1 60 60 CK19 ISH internal control negative 1 tongue 4 pT2N2b
3464 LN SCC 1 2 60 120 0 0 0 0
3549 Primary SCC 0 0 0 0 1 1 <5 <5 Focal minimal 0 tongue 3 pT2N1
3549 LN SCC 0 0 0 0 1 1 <5 <5 Focal minimal
3496 Primary SCC 0 0 0 0 1 1 10 10 hard palate 2 pT2N0
3496 LN No tumour
3500 Primary SCC 0 0 0 0 CK19 ISH external negative contol positive 0 tongue 2 pT2N0
3500 LN No tumour
3449 Primary SCC 0 0 0 0 0 0 0 0 1 tongue (lateral) 1 pT1N0
3449 LN No tumour
3545 Primary SCC 0 0 0 0 1 2 50 100 0 tongue 2 pT2N0
3545 LN No tumour
3551 Primary SCC 1 2 100 200 1 2 50 100 NR FOM 2 pT2N0
3551 LN No tumour
3556 Primary SCC 0 0 0 0 1 1 10 10 NR tongue (ventral) 2 pT2N0
3556 LN No tumour
3567 Primary SCC 1 1 20 20 1 1 70 70  1 tongue 4 pT2N2b
3567 LN SCC 1 2 70 140 1 1 70 140
3571 Primary SCC 0 0 0 0 0 0 0 0 1 buccal pT2N0
3571 LN No tumour
21 5 29 5 18
43 8 39 9 26
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CK19
qRT-PCR
(sample A)
sample no
present/
absent
present/
absent.
semi-
quantitation
present/
absent, qRT comments site stage pathology pathology comment
L1 0 NR 1 tongue (ventral) 4 pT2N2b
L2 0 0 (-) 0 maxilla 2 pT2N0
L3 0 1 `+ 0 tongue 3 pT3N0
L4 1 1 `++ 1
L5 1 1 `++ 1 maxilla 4a pT4N0
L6 0 1 `+ 0 FOM 4a pT4N0
L8 1 1 `++ 1 FOM 4a pT4N2c
L9 ND 1 `+ 0 buccal 2 pT2N0
L10 1 1 `++ 1 FOM 4a pT4No
L11 1 1 `++ 1 tongue 3 pT3N1
L12 1 1 `++ 1 tongue 4a pT4N1
L13 0 1 `+ 0 tongue (lateral) 4 pT2N2C
L14 1 1 `++ 1 tongue (ventral)/FOM 4a pT4N0
L15 0 0 (-) 0 mandibular alveolus 4a pT4N0
L17 1 1 `++ 1 FOM 4a pT4N0
L18 0 0 (-) 0 gingiva 4a T4aN0 verrucous carcinoma carcinoma
L19 1 1 `++ 1 tonsil/BOT 4a pT3N2b
L20 0 0 (-) 0 FOM 4 pT2N2b
L21 ND 1 `+ 1 Mandible 4a pT4N0
L22 1 1 `++ 1 alveolus 2 pT2N0
L23 1 1 `++ 1 tongue (lateral) 4a pT4N1
L24 ND 0 (-) 0 tongue (lateral) 3 pT3N0
L25 0 0 (-) 0 mandible 4a pT4N0
L26 ND 0 (-) 0 tongue (lateral) 4a pT3N2b
L27 0 0 (-) 0 maxilla 4a pT4aN0 adenoid cystic carcinoma
L28 1 ND ND tongue (lateral) 4a pT2N2b
L30 1 1 `++ 1 retromolar 4a pT2N2b
L31 0 1 `++ 0 retromolar 3 pT3N0
L32 1 1 `++ 1 RFOM 3 pT3N0
L34 ND 1 `+ 1 mandible 4a pT4N1
L35 0 1 `+ 0 tongue 4a pT3N2c
L36 1 1 `++ 1 maxilla 4a pT4aN0 trnasitional type SCC
L38 1 1 `+ 1 tongue (lateral) 4a pT2N2b
L40 1 1 `++ 1 tongue 4a pT3N2b
L41 0 0 (-) 0 maxilla 4b pT4bN2b
CK19 OSNA (sample B) CK19 qRT-PCR
(sample B)
Clinicopathological data
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L42 0 1 `++ 0 retromolar 3 pT3N1
L43 0 1 `+ 0 maxilla 4a pT4aN2b
L44 1 1 `++ 1 tonsil 3 pT1N1 baslaoid SCC IS negative
L45 1 1 `++ 1 tonsil 4a pT2N3 ISH positive
L46 1 1 `++ 1 maxilla 4a pT4aNX
L47 0 1 `++ 1 tongue 3 pT2N1
L48 1 1 `++ 1 tonsil 3 pT2N1 ISH negative
L49 1 1 `++ 1 tonsil 3 pT3N0 ISH negative
L50 ND 1 `+ 1 tongue 3 pT3N1
L51 1 1 `+ 1 mandible 4a pT4aN0
`+ve  n= 23 34 27
n= 39 43 44
C1 1 (++) 1 Gingiva 4 Salivary tissue  - no tumor
C2 1 (++) 1 Tongue 2
C3 0 (-)L 0 Tongue 3
C4 0 (-) 0 Tongue/floor of mouth 3
C5 1 (+) 1 Gingiva 4
C6 1 (++) 1 Tongue 3 Normal tissue
C7 NR NR low GAPDH Floor of mouth 4 Normal tissue
C8 1 (++) 1 Tongue 3 Salivary tissue  - no tumor
C9 NR NR low GAPDH Gingiva + buccal 3
C10 1 (++) 1 Gingiva 3
C11 1 (++) 1 FOM 3 no tumor or salivary tissue
C12 NR NR low GAPDH Tongue 3
C13 1 (++) 1 Cheek/gingiva 4
C14 1 (++) 1 Tongue 3
C15 1 (+) 1 Tongue 3
C16 1 (+) 1 Tongue 3
C17 1 (+) 1 Gingiva 4
C18 1 (++) 1 Gingiva 4
C19 1 (++) 1 Cheek 3
C20 NR 0 low GAPDH Regio maxillars 3 Veruccous carcinoma
C21 1 (++) 1 Tongue 3
C22 1 (++) 1 Gingiva 4
C23 1 (++) 1 Tongue 2
C24 0 (-) 0 gingiva 4
C25 0 (-) 0 Tongue 3
C26 1 (+) 1 Gingiva 3
C27 1 (++) 1 Floor of mouth/gingiva 4 Sparce tumor tissue
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C28 1 (+) 0 Tongue/ganebue 3
C29 1 (++) 1 Tongue 3
C30 1 (+) I 0 FOM 3
C31 1 (++) 1 Tongue 3
C32 1 (++) 1 Tongue 3
C33 1 (++) 1 Tongue/floor of mouth 3
C35 1 (++) 1 Tongue 3
C36 0 (-) 0 Gingiva 3
C37 NR NR low GAPDH Tongue 2 Tumor and necrosis
C39 1 (++) 1 Floor of mouth 3
C40 1 (+) 1 Gingiva 4
C41 1 (+) 1 Tongue 3
C42 1 (++) 1 Hard palate 4
C43 1 (++) 1 Tongue 3
C44 0 (-) 0 Hard palate 3
C45 NR 0 Tongue 3
`+ve n= 31 29
n= 37 39
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Supplementary Table 2. Distribution of CK19 expression by OSNA and stage 
 OSNA 
+ - 
Stage II  4 1 
Stage III  30 6 
Stage IV  30 6 
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